New selective and potent A2AR antagonists were initially developed for neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and attention-deficit/hyperactivity disorder (ADHD) [13,14,15,16]. The gene discussed is ADORA2A; the disease is neurodegenerative disease.